Top Stocks in Trading News: Tyson, Gilead, Clorox, Zoltek, Threshold
Tyson Foods, Inc. (NYSE:TSN): In FY12, overall domestic protein, including chicken, beef, pork and turkey production is expected to decrease. Because exports are likely to remain strong, we forecast total domestic availability of protein to be down 2-3% compared to FY11, which should continue to support improved pricing. Shares of Tyson Foods, Inc. are trading 5.64% higher today.
Gilead Sciences, Inc. (NASDAQ:GILD): After Gilead reported higher than expected Q4 revenue, Oppenheimer believes that the company’s 2012 guidance is conservative and expects sales of the company’s HIV treatments to continue to grow. The firm maintains an Outperform rating. Shares of Gilead Sciences, Inc. are trading 7.79% higher today.
The Clorox Company (NYSE:CLX): The company also expects 2%-4% revenue growth for the year. Shares of The Clorox Company are trading 1.76% higher today.
Zoltek Companies, Inc. (NASDAQ:ZOLT): CEO Zsolt Rumy commented: “We estimate that this large turbine segment of wind energy generation will increase at an annual rate of 15-25% for the next decade or more. These positive market fundamentals should enable us to maintain and build upon their leadership position as the primary supplier of carbon fiber to producers of wind turbines.” Shares of Zoltek Companies, Inc. are trading 38.24% higher today.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD): Threshold Pharmaceuticals announced that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug. TH-302 is currently being investigated in a global Phase 3 clinical trial in patients with soft tissue sarcoma, a randomized Phase 2 trial in patients with advanced pancreatic cancer from which top-line results are expected in February, as well as additional clinical studies in other solid tumors and hematological malignancies. Merck (NYSE:MRK) will receive co-development rights, exclusive global commercialization rights and will provide Threshold an option to co-commercialize the therapeutic in the U.S. In exchange, Threshold will receive an upfront payment of $25M and could receive up to $35M in additional development milestones during 2012. Threshold is also eligible to receive a $20M milestone payment based on positive results from its randomized Phase 2 trial in pancreatic cancer. Total potential milestone payments are $525M, comprised of $280M in regulatory and development milestones and $245M in sales-based milestones. In the U.S., Threshold will have primary responsibility for development of TH-302 in the soft tissue sarcoma indication. Threshold and Merck KGaA will jointly develop TH-302 in all other cancer indications being pursued. Merck KGaA will pay 70% of worldwide development costs for TH-302. Shares of Threshold Pharmaceuticals, Inc. are trading 77.51% higher today.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com